During Wednesday's Lightning Round segment of Mad Money one caller asked Jim Cramer about Amarin Corp. (AMRN) : "This is speculative and should only be bought as a spec," he replied about the biopharma company that develops and markets medicines for cardiovascular disease.
More from Investing
The strength in the Russell 2000 is a positive sign for stock-picking.
Amid the Fed's shift in tone and the market's reaction, I'm eyeing Apex Technology Acquisition.
Here's what Jim Cramer has to say about the stock.
While the Fed hasn't made any actual rate policy changes, seven Fed members are now predicting a hike in 2022 vs. four previously.